Literature DB >> 8825337

Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery.

S J Lydford1, K C McKechnie, I G Dougall.   

Abstract

1. In isolated ring preparations of the rabbit saphenous vein, prostaglandin E2 (PGE2) caused well-defined, stable and concentration-dependent relaxations of KCl contracted tissues with a mean potency (p[A50]) of 9.39. 2. The prostanoid EP-receptor agonists, PGE1, 11-deoxy PGE1, 16,16-dimethyl PGE2 and misoprostol were all full agonists in this preparation. The EP2-receptor selective agonists, butaprost and AH13205, and the EP1/EP3-receptor selective agonist, sulprostone, also relaxed this tissue but were at least 300 times less potent than PGE2. 3. Prostaglandin D2 (PGD2), the DP-receptor agonist, BW245C, and the IP-receptor agonist, cicaprost, caused concentration-dependent relaxations of the rabbit saphenous vein but were at least 60 times less potent than PGE2. 4. The selective EP4-receptor antagonist, AH23848B (30 microM), antagonized the PGE2 concentration-effect (E/[A]) curves yielding a pA2 estimate of 4.96. The EP1/DP-receptor antagonist, AH6809 (10 microM), had no effect on the location of PGE2 E/[A] curves. 5. The stable thromboxane A2-mimetic, U46619, elicited concentration-dependent contractions of the rabbit saphenous vein (p[A50] = 8.01) however, PGE2 and prostaglandin F2 alpha (PGF2 alpha) were unable to produce a contractile response. The response to U46619 was competitively antagonized by the TP-receptor antagonist, GR32191B, yielding a pKB estimate of 7.08. 6. In the rabbit isolated ear artery, PGE2, misoprostol and AH13205 relaxed tissues pre-contracted with phenylephrine. PGE2 (p[A50] = 7.04) and misoprostol were equipotent, whereas AH13205 was some 40 fold less potent. AH23848B (30 microM) and AH6809 (1 and 10 microM) caused no significant shift in the location of PGE2 E/[A] curves. 7. These data suggest that the rabbit isolated saphenous vein contains prostanoid, EP-, DP-, IP- and TP-receptors. Based on antagonist affinity information and agonist potency orders, the rabbit saphenous vein contains an inhibitory prostanoid EP-receptor different from that in the rabbit ear artery, but comparable to the recently described EP4-receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825337      PMCID: PMC1909359          DOI: 10.1111/j.1476-5381.1996.tb15148.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Characterization of P2x-receptors in rabbit isolated ear artery.

Authors:  S E O'Connor; B E Wood; P Leff
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor.

Authors:  A Watabe; Y Sugimoto; A Honda; A Irie; T Namba; M Negishi; S Ito; S Narumiya; A Ichikawa
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

3.  Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity.

Authors:  T Namba; Y Sugimoto; M Negishi; A Irie; F Ushikubi; A Kakizuka; S Ito; A Ichikawa; S Narumiya
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

4.  Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype.

Authors:  L Bastien; N Sawyer; R Grygorczyk; K M Metters; M Adam
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

5.  Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase.

Authors:  A Irie; Y Sugimoto; T Namba; A Harazono; A Honda; A Watabe; M Negishi; S Narumiya; A Ichikawa
Journal:  Eur J Biochem       Date:  1993-10-01

6.  Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype.

Authors:  C D Funk; L Furci; G A FitzGerald; R Grygorczyk; C Rochette; M A Bayne; M Abramovitz; M Adam; K M Metters
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

7.  Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype.

Authors:  A Honda; Y Sugimoto; T Namba; A Watabe; A Irie; M Negishi; S Narumiya; A Ichikawa
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

8.  Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins.

Authors:  Y Sugimoto; M Negishi; Y Hayashi; T Namba; A Honda; A Watabe; M Hirata; S Narumiya; A Ichikawa
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

9.  Cloning and expression of a cDNA for mouse prostaglandin F receptor.

Authors:  Y Sugimoto; K Hasumoto; T Namba; A Irie; M Katsuyama; M Negishi; A Kakizuka; S Narumiya; A Ichikawa
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

10.  cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla.

Authors:  T Namba; H Oida; Y Sugimoto; A Kakizuka; M Negishi; A Ichikawa; S Narumiya
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

View more
  18 in total

1.  PGF(2alpha), a prostanoid released by endothelial cells activated by hypoxia, is a chemoattractant candidate for neutrophil recruitment.

Authors:  T Arnould; R Thibaut-Vercruyssen; N Bouaziz; M Dieu; J Remacle; C Michiels
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes.

Authors:  Richard J Wilson; Heather Giles
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

3.  Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.

Authors:  R L Jones; H Wise; R Clark; R L Whiting; K R Bley
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

4.  Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists.

Authors:  J Y Crider; B W Griffin; N A Sharif
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

5.  The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation.

Authors:  C Rouaud; M Delaforge; M Anger-Leroy; G Le Filliatre; M Finet; R Hanf
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Prostaglandin E(2) increases cyclic AMP and inhibits endothelin-1 production/secretion by guinea-pig tracheal epithelial cells through EP(4) receptors.

Authors:  S Pelletier; J Dubé; A Villeneuve; F Gobeil; Q Yang; B Battistini; G Guillemette; P Sirois
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

7.  Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.

Authors:  T L Davis; N A Sharif
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells.

Authors:  C L Chan; R L Jones; H Y Lau
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

9.  Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.

Authors:  Martin Leduc; Xin Hou; David Hamel; Melanie Sanchez; Christiane Quiniou; Jean-Claude Honoré; Olivier Roy; Ankush Madaan; William Lubell; Daya R Varma; Joseph Mancini; François Duhamel; Krishna G Peri; Vincent Pichette; Nikolaus Heveker; Sylvain Chemtob
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

Review 10.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.